Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSC) potently repress antitumor immunity. The amount of MDSC in the blood of melanoma patients declines in response to vemurafenib, an inhibitor of oncogenic BRAF signaling that abrogates the ability of malignant cells to induce MDSC. This suggests that vemurafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilling, Bastian, Paschen, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805652/
https://www.ncbi.nlm.nih.gov/pubmed/24167759
http://dx.doi.org/10.4161/onci.25218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805652/
https://www.ncbi.nlm.nih.gov/pubmed/24167759
http://dx.doi.org/10.4161/onci.25218

Ejemplares similares